Fas/FasL expression in colorectal cancer. An immunohistochemical study.
Authors:
- Anna PryczyniczAPAnna Pryczynicz
- Katarzyna Guzińska-UstymowiczKGKatarzyna Guzińska-Ustymowicz
- Andrzej KemonaAKAndrzej Kemona
Open Access
- 13 November 2010
- journal article
- research article
- Published by VM Media Group sp. z o.o in Folia Histochemica et Cytobiologica
- Vol. 48 (3) , 425-429
Abstract
Fas/FasL expression in colorectal cancer. An immunohistochemical study.Keywords
This publication has 14 references indexed in Scilit:
- The “Fas counterattack” is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instabilityHuman Pathology, 2008
- Fas expression in primary breast cancer is related to neoplastic infiltration of perilymphatic fatAdvances in Medical Sciences, 2008
- Fas ligand expression in colon cancer: A possible mechanism of tumor immune privilegeWorld Journal of Gastroenterology, 2005
- Fas ligand and tumour counter‐attack in colorectal cancer stratified according to microsatellite instability statusThe Journal of Pathology, 2003
- Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancerEuropean Journal of Gastroenterology & Hepatology, 2003
- Fas ligand is up-regulated during the colorectal adenoma–carcinoma sequenceEuropean Journal of Surgical Oncology, 2002
- The Fas Death FactorScience, 1995
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993
- Apoptosis and diseaseThe Lancet, 1993
- Lymphocytic infiltration and survival in rectal cancer.Journal of Clinical Pathology, 1986